Trevena (TRVN) Stock Price

Trevena Price

NASDAQ·CLOSED
0.00
​
Market closed

Over the last 12 years Trevena grew revenue by 2.1% annually, reaching 3.13 M USD. For Trevena, the net margin of -1,289.2% is up versus -80,229.0% a few years ago.

Trevena stock price

Access this data via the Eulerpool API

Trevena business model & stock analysis

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2014-01-31. The firm is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. The company is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. The company is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. The company is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Frequently asked questions about Trevena

6 analysts currently rate the Trevena stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Trevena to generate revenue of 3.00 M USD and earnings per share of -0.31 USD.

Converted at the current exchange rate, the Trevena share trades at 0.00 EUR (0.00 USD).

The Trevena share (TRVN) is listed on 5 stock exchanges, including: NASDAQ (TRVN), SIX (Zürich) (6T4.SW), Frankfurt (6T4.F), München (6T4.MU), Düsseldorf (6T4.DU).

The expected revenue of Trevena is 3.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Trevena is -213,948.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Trevena is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Trevena stock.

The price-to-sales ratio (P/S) of Trevena is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Trevena stock.

The Eulerpool Quality Score for Trevena is 3/10.

The ISIN of Trevena is US89532E3071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Trevena is A1XDSL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Trevena is TRVN. The ticker symbol is used to trade Trevena shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
130,208.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website trevena.com
Currency
USD
Initial public offering
Jan 31, 2014
ISIN
US89532E3071
Cusip
89532E109
Sedol
BGDW0N7
Market capitalization
203.76 USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
0.00
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/S
P/Se
—
EV/EBIT
1.00
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-173.89 %
Gross Margin
46.56 %
EBIT Margin
-1,129.22 %
Net Margin
-1,289.25 %
EPS (Earnings Per Share)
-58.25 USD
Net Debt / EBIT
1.00
Debt/Equity
-4.03
Last updated Oct 4, 2026, 12:08 PM

Trevena Ticker

DÜSSELDORF · 6T4.DUFRANKFURT · 6T4.FMUNICH · 6T4.MUNASDAQ · TRVNSIX · 6T4.SW

All fundamentals and in-depth analysis of Trevena

Our stock analysis for Trevena stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trevena. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.